drugset / Trial / NCT06285643
A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.
Timeline
- Start
- 2024-06-11
- Primary completion
- 2028-08-31
- Completion
- 2028-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AAV2-GDNF | Gene therapy (AAV / viral vector) | — | Other |